RudaCure Inc. a été sélectionnée pour le Ministère de SMEs and Startups' 2021 Big3 Commercialization Support Project, which will support the commercialization not only of the actuellement ongoing RCI001, but also of traitement de la douleur RCI002, atopic dermatitis treatment RCI003, anti-metastatic cancer treatment RCI004, and age-related macular degeneration treatment RCI005.
Along with the previously selected Ministère de Science and ICT Bio iCORE project, l'entreprise received high scores from evaluators across divers fields for its national and international commercialization activities.
En particulier, for this Big3 Commercialization Project, l'entreprise a été reconnue pour its ability to secure core technology development through excellent technical personnel and research facilities, ainsi que the management team's capability in technology development and clinical advancement. En conséquence, l'entreprise will receive KRW 150 million in funding through the end of cette année.
L'entreprise plans to devote all efforts to increasing the value of the drugs actuellement under development by accelerating national and international business activities through divers gouvernement programme de soutiens.